MoonLake Immunotherapeutics Class A (MLTX)

MoonLake Immunotherapeutics' stock price has been volatile over the past six months, with a 52-week range between $5.95 and $62.75. As of late March 2026, the share price was around $17.75, a 55.45% decline from the previous year. Key events include positive Phase 3 clinical trial results for Sonelokimab in HS, where 62% of patients achieved a HiSCR75 response by Week 40. Positive Phase 2 clinical trial results for Sonelokimab in axial spondyloarthritis were also reported, with 81% of patients achieving a clinically meaningful response at Week 12. The FDA provided positive feedback on the regulatory pathway for Sonelokimab in HS, suggesting that substantial evidence of effectiveness could be established without additional clinical trials. Buyout speculation also fueled retail interest in the stock. In November 2025, the company reported holding $380.5 million in cash, expected to fund operations into the second half of 2027.

Information regarding specific demand seasonality for MoonLake Immunotherapeutics' products is not readily available. As a clinical-stage biopharmaceutical company, its focus is on the development and clinical trials of Sonelokimab, rather than commercial sales. Therefore, traditional demand seasonality does not yet apply.

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory skin and joint diseases. Their primary product, Sonelokimab (SLK), is a tri-specific Nanobody designed to inhibit IL-17A and IL-17F, targeting conditions like hidradenitis suppurativa (HS), psoriatic arthritis (PsA), axial spondyloarthritis (AxSpA), palmoplantar pustulosis, and psoriasis.

MoonLake Immunotherapeutics is headquartered in Zug, Switzerland, with offices in the UK and Portugal. The company also has a growing presence in Cambridge's biotech ecosystem.

MoonLake Immunotherapeutics' brand reputation appears positive, driven by promising clinical trial results and regulatory progress. The positive Phase 3 VELA trial results for Sonelokimab in hidradenitis suppurativa and Phase 2 trial results in axial spondyloarthritis have been a significant boost. Favorable FDA feedback regarding the regulatory pathway for Sonelokimab in HS has also contributed positively. Buyout speculation suggests recognition of the company's value. MoonLake actively participates in healthcare conferences and hosts investor days, maintaining transparency and engagement.

MoonLake Immunotherapeutics' stock is primarily held by institutional investors, owning approximately 51.75% to 54.65% of the company. Insiders hold around 36.40%, while public companies and individual investors own a smaller percentage, ranging from 0.61% to 8.95%. Major institutional owners include BVF Inc/il, Deep Track Capital, LP, and Cormorant Asset Management, LP.